DYSCO: Minimal Clinically Significant Difference (MCID) of Multidimensional Dyspnea Profile (MDP) in COPD Patients Undergoing Respiratory Rehabilitation

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06012006
Collaborator
(none)
120
1
14

Study Details

Study Description

Brief Summary

This study is designed to determine the individual threshold of minimal clinical change (MCID) for each component of the Multidimensional Dyspnea Profile (MDP) questionnaire in COPD patients undergoing pulmonary rehabilitation.

Condition or Disease Intervention/Treatment Phase
  • Other: constant work-rate cycling exercise test
N/A

Detailed Description

The aim of the research is to determine the minimal clinically significant difference (MCID) in MDP scores in COPD patients after a respiratory rehabilitation course using the anchoring method :

  • The A1 score will be compared with the Borg Affective Dyspnea (BorgA) scale.

  • The sensory score will be compared with the Borg Sensory Dyspnea Scale (BorgS).

  • The 5 sensory items will be compared with the Borg Sensory Dyspnea scale.

  • The emotional score will be compared with the Borg Emotional Dyspnea Scale.

  • The 5 emotional items will be compared with the Borg affective dyspnea scale. The various questionnaires will be administered to patients at inclusion, after a constant work-rate cycling exercise test, and at isotime during the same cycling exercise test at the end of the pulmonary rehabilitation course.

The sensitivity study will be conducted using the visual analog dyspnea scale instead of the Borg score. Finally, we will also determine the MCID using the distribution method. The MCID score will be correlated with various quality of life and physical performance scores.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Determination of the Minimal Clinically Significant Difference (MCID) of Multidimensional Dyspnea Profile (MDP) Scores in Chronic Obstructive Pulmonary Disease (COPD) Patients During Pulmonary Rehabilitation
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Oct 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: pulmonary rehabilitation

COPD patients will be admitted for pulmonary rehabilitation, the duration and modalities of which vary from center to center.

Other: constant work-rate cycling exercise test
Description: at the end of pulmonary rehabilitation, a constant work-rate second cycling exercise test will be performed with the same duration as the cycling exercise test at inclusion

Outcome Measures

Primary Outcome Measures

  1. multidimensional (MDP) questionnaire [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    The multidimensional questionnaire measuring the sensory component of dyspnea (intensity of the 5 respiratory descriptors) and the affective component of dyspnea (immediate discomfort and intensity of emotional responses). The MDP will be carried out at the end of the constant work-rate cycling exercise test, taking into account the last 30 seconds.

  2. sensory Borg scale [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    The two Borg scales will be carried out at the end of the constant work-rate cycling exercise test, taking into account the last 30 seconds.

  3. affective Borg scale [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    The two Borg scales will be carried out at the end of the constant work-rate cycling exercise test, taking into account the last 30 seconds.

Secondary Outcome Measures

  1. Affective and Sensory dyspnea visual analog scale (VAS) [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    Affective and sensory dyspnea VAS will be carried out at the end of the constant work-rate cycling exercise test, taking into account the last 30 seconds.

  2. mMRC (Modified Medical Research Council) dyspnea score [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    This 5-level score assesses the intensity of dyspnea. The consideration period will be one week.

  3. Dyspnoea 12 [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    Multidimensional dyspnea questionnaire comprising 12 items (7 sensory and 5 affective) that can be rated from 0 (absent) to 3 (severe), i.e. a score from 0 to 36. This questionnaire measures dyspnoea over the period "these days". The consideration period will be one week

  4. COPD Assessment Test (CAT) score [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    This questionnaire comprises 8 questions on a scale from 0 (best condition) to 5 (worst condition). The total score corresponds to the sum of the scores for each question: it ranges from 0 to 40.The consideration period will be one week.

  5. Hospital Anxiety and Depression scale (HADS) [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    Anxiety and depression, measured by the two subscore of the HADS scale. Each subscore comprises 7 items rated from 0 (no symptoms) to 3. Seven questions relate to anxiety (total A) and seven questions relate to depression enabling us to obtain the score (maximum score = 42)The consideration period will be one week.

  6. Saint George Respiratory Questionnaire (SGRQ) [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    evaluated by a total score and three sub-scores (symptoms, activity and impact). The total score and each sub-score are scaled from 0 to 100. The higher the score, the poorer the quality of life.The consideration period will be one week.

  7. VQ11 [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    questionnaire consisting of 11 questions evaluated by a total score and 3 sub-scores (functional - 3 items, psychological: 4 items; relational - 4 items). Each question has 5 possible response levels, with ratings on a Likert scale ranging from 1 (not at all) to 5 (extremely). The functional, psychological and relational scores are respectively rated out of 15 for the first and 20 for the last two. The total score ranges from 11 to 55. A VQ11 total score greater than or equal to 22 reflects a patient's poor health-related quality of life.

  8. lung function tests [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    FEV1 measurement (before and after bronchodilation), FEV1/FVC measurement, inspiratory capacity (IC) measurement, RV measurement (optional)

  9. 6 minutes walk test [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    Distance

  10. rise chair test (optional) [at inclusion and then, up to 6 weeks (at the end of pulmonary rehabilitation course)]

    number of rise

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Gold B or D COPD patient

  • Moderate to severe obstructive ventilatory disorder (FEV1<80%)

  • Admitted for a pulmonary rehabilitation

  • Having given free, informed and written consent

Exclusion Criteria:
  • Lack of French language skills, preventing completion of questionnaires

  • Cognitive impairment preventing completion of questionnaires

  • Patient under guardianship

  • Patient not affiliated to the social security system

  • Chronic ethylism

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Principal Investigator: Capucine Morelot-Panzini, MD, PhD, APHP

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT06012006
Other Study ID Numbers:
  • APHP221339
First Posted:
Aug 25, 2023
Last Update Posted:
Aug 25, 2023
Last Verified:
Jul 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Assistance Publique - Hôpitaux de Paris
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 25, 2023